Dr. Chet R. Villa of Cincinnati Children's Hospital Medical Center detailed how the 12-month FIGHT DMD trial demonstrated a 5.4% improvement in left ventricular ejection fraction compared to control groups. Beyond these functional gains, new 36-month data from an open-label extension highlight favorable safety profiles and specific biological markers of tissue repair. Patients treated with ifetroban showed a 30% reduction in MYL3 and a 50% reduction in MYOD1, both of which are circulating indicators of heart muscle damage.
In section Releases
Cumberland Pharmaceuticals Reports New Data on Ifetroban for DMD
Updated Phase 2 results for ifetroban, an experimental treatment for Duchenne muscular dystrophy, reveal significant reductions in cardiac injury markers. Presented at the Parent Project Muscular Dystrophy conference in Orlando, the findings suggest the oral therapy may effectively slow the heart damage that serves as the leading cause of mortality in DMD patients.
These results address a significant gap in pediatric care, as no FDA-approved therapies currently target the underlying cardiac complications inherent to Duchenne muscular dystrophy. Cumberland Pharmaceuticals plans to continue long-term treatment analyses and supportive studies to further validate ifetroban’s efficacy. Pat Furlong, CEO of Parent Project Muscular Dystrophy, noted that the data provide a promising path toward a specialized treatment for families navigating the universal cardiac risks of the disease.
Comments (0)
No comments yet. Be the first!